tiprankstipranks
Molecular Partners (MOLN)
NASDAQ:MOLN
US Market
MOLN
Molecular Partners
RESEARCH TOOLSreports
Want to see MOLN full AI Analyst Report?

Molecular Partners (MOLN) Earnings Dates, Call Summary & Reports

48 Followers

Earnings Data

Report Date
Aug 25, 2026
TBA (Confirmed)
Period Ending
2026 (Q2)
Consensus EPS Forecast
-0.44
Last Year’s EPS
-0.69
Same Quarter Last Year
Analyst Consensus
Strong Buy
Based on 3 Analysts Ratings

Earnings Call Summary

Q4 2024
Earnings Call Date:Mar 06, 2025|
% Change Since:
|
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in Molecular Partners' programs, particularly in the radio DARPin franchise and the improved efficacy of the 533-DARPIn program. The expansion of the Orano Med collaboration and strong financial position further bolster the company's outlook. However, the discontinuation of the Novartis collaboration and initial challenges with the T Cell Engager program were noted as setbacks. Overall, the highlights significantly outweigh the lowlights.
Company Guidance
During the Molecular Partners Fourth Quarter and Full Year 2024 Results Call, several key metrics and strategic developments were highlighted. The company reported operating expenses of CHF 66 million for the year, which was within their guidance range of CHF 65 million to CHF 70 million. They ended the year with a cash balance of CHF 149 million, having raised CHF 20 million in a financing round in October, and reported a cash burn of approximately CHF 54 million for the year. This funding positions them well financially, with a runway extending into 2027. Revenue for 2024 was CHF 5 million, primarily from their collaboration with Novartis, which has now concluded. The company is advancing its radio DARPin program, with their lead candidate MP0712 set to begin clinical trials and dosimetry studies in 2025. The expansion of their collaboration with Orano Med was also a significant milestone, securing access to 10 product slots for the promising isotope Lead-212. Additionally, Molecular Partners is continuing to refine its T cell engager platform, with plans to densify dosing schedules and further investigate premedication strategies in upcoming trials.
Successful Year of Execution
Molecular Partners successfully executed their plans in 2024, advancing programs toward clinical readouts and expanding their collaboration with Orano Med.
Lead DARPin Program Progress
The radio DARPin franchise showed significant progress with the lead compound DLL3 targeting 712 passing all IND-enabling studies and ready to enter clinical trials.
Strategic Collaboration with Orano Med
Molecular Partners expanded their collaboration with Orano Med to secure isotope supply for 10 products, enhancing their radio DARPin franchise.
Strong Financial Position
Ending the year with CHF149 million in cash, the company is well-capitalized with a runway into 2027, ensuring continued investment in their pipeline.
Improved Efficacy in T Cell Engager Program
The 533-DARPIn program for AML showed promising results with three complete responses out of eight patients after adjustments in dosing regimen.

Molecular Partners (MOLN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
Daily Earnings Calendar >

MOLN Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Aug 25, 2026
2026 (Q2)
-0.44 / -
-0.686―――
Mar 12, 2026
2025 (Q4)
-0.40 / -0.43
-0.363-19.83% (-0.07)―
Aug 25, 2025
2025 (Q2)
-0.47 / -0.69
-0.517-32.69% (-0.17)―
Mar 06, 2025
2024 (Q4)
-0.45 / -0.36
-0.67846.46% (+0.32)
Aug 26, 2024
2024 (Q2)
- / -0.52
-0.97847.14% (+0.46)
Mar 14, 2024
2023 (Q4)
-1.11 / -0.68
-1.07737.05% (+0.40)
Aug 24, 2023
2023 (Q2)
-0.99 / -0.98
4.955-119.74% (-5.93)
Mar 09, 2023
2022 (Q4)
-0.94 / -1.08
-0.979-10.01% (-0.10)
Aug 25, 2022
2022 (Q2)
4.17 / 4.96
-1.117543.60% (+6.07)――
Mar 15, 2022
2021 (Q4)
-0.62 / -0.98
-1.49934.69% (+0.52)――
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

MOLN Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Mar 12, 2026
$4.71$4.22-10.40%
Aug 25, 2025
$4.22$3.89-7.82%
Mar 06, 2025
$4.90$5.01+2.24%
Aug 26, 2024
$6.19$6.92+11.79%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Molecular Partners (MOLN) report earnings?
Molecular Partners (MOLN) is schdueled to report earning on Aug 25, 2026, TBA (Confirmed).
    What is Molecular Partners (MOLN) earnings time?
    Molecular Partners (MOLN) earnings time is at Aug 25, 2026, TBA (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is MOLN EPS forecast?
          MOLN EPS forecast for the fiscal quarter 2026 (Q2) is -0.44.